65 and older, any sex, with Covid19 or SARS-CoV Infection. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Change in COVID-19 SeverityPrimary· Baseline, Day 2, 8, 10, 14, 30, 90 and 180
The Ordinal Scale for Clinical Improvement was used to assess change in COVID-19 Severity. The scale has a minimum value of 0 (no clinical or virological evidence of infection) and a maximum value of 8 (death) with higher scores indicating a worse outcome.
Baseline to Day 2
Group
Value
95% CI
Treatment Group
1.88
± 0.31
Placebo Group
2
± 0
Baseline to Day 8
Group
Value
95% CI
Treatment Group
2
± 0
Placebo Group
2
± 0
Baseline to Day 10
Group
Value
95% CI
Treatment Group
2
± 0
Placebo Group
2
± 0
Baseline to Day 14
Group
Value
95% CI
Treatment Group
2
± 0
Placebo Group
2
± 0
Baseline to Day 30
Group
Value
95% CI
Treatment Group
2
± 0
Placebo Group
2
± 0
Baseline to Day 90
Group
Value
95% CI
Treatment Group
2
± 0
Placebo Group
2
± 0
Baseline to Day 180
Group
Value
95% CI
Treatment Group
2
± 0
Placebo Group
2
± 0
Adverse events — posted to ClinicalTrials.gov
Time frame: Adverse events were collected from baseline to end of study for approximately 6 months (180 days) for all subjects..
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
The purpose of this study is to test whether Fisetin, a senolytic drug, can assist in preventing an increase in the disease's progression and alleviate complications of coronavirus due to an excessive inflammatory reaction.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity
· Phase 1, PHASE2
· recruiting
NCT07195318 — Fisetin Supplementation for Healthy Aging
· NA
· recruiting
NCT07025226 — Sequential Treatments or Combinations Including Dasatinib, Quercetin, Fisetin and/or Temozolomide for the Treatment of P
· EARLY_PHASE1
· recruiting
NCT06113016 — Prevention of Frailty With Fisetin and Exercise in Breast Cancer Survivors
· Phase 2
· recruiting
NCT06133634 — Fisetin to Improve Vascular Function in Older Adults
· Phase 1, PHASE2
· active not recruiting
Other recruiting trials for Covid19
Currently open trials in the same condition.
NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix
· EARLY_PHASE1
· active not recruiting
NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation
· NA
· recruiting
NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs
· NA
· active not recruiting
NCT05013632 — COVID-19 International Drug Pregnancy Registry
· recruiting
NCT04806061 — Urine Alkalinisation in COVID-19
· NA
· active not recruiting
Other Mayo Clinic trials
Trials by the same sponsor.
NCT07126548 — A Point of Prostate Cancer Diagnosis Virtual Reality Assistant Intervention in Supporting Newly Diagnosed Black Men
· NA
· not yet recruiting
NCT07221656 — Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration
· not yet recruiting
NCT06891001 — The Utilization of a Shoe Insert on Individuals With Unilateral Greater Trochanteric Pain Syndrome on Single Leg Stance,
· NA
· not yet recruiting
NCT07169799 — Impact of Cryotherapy Spray (Tru-Freeze) for the Eradication of Gastric Antral Vascular Ectasia (ICE-GAVE)
· NA
· recruiting
NCT07086183 — Perioperative Risk in Patients on Chronic Aspirin Undergoing Craniotomy
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mayo Clinic
Last refreshed: 26 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04537299.